Citation:
B Hirsh Raccah, Yanovsky, A, Treves, N, Rotshild, V, Renoux, C, Danenberg, H, Eliaz, R, ו Matok, I. 2021. “Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Inhibitors And The Risk For Neurocognitive Adverse Events: A Systematic Review, Meta-Analysis And Meta-Regression”. Int J Cardiol, 335, Pp. 7–14.
תקציר:
{It has been suggested that lipid lowering therapy causes impaired cognitive changes. The association between the use of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk of neurocognitive adverse events remains unclear. This meta-analysis aims to assess neurocognitive safety of PCSK9 inhibitors in randomized controlled trials (RCTs).\\ = -0.0037